April 6, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares over potential securities laws violations by Adamis Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) concerning whether a series of statements by Adamis Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On March 27, 2015, Adamis Pharmaceuticals Corp announced that it had received a Complete Response Letter from the U.S. Food & Drug Administration ('FDA') regarding the Company's New Drug Application ('NDA') for its Epinephrine Injection USP 1:1000 0.3mg Pre-filled Single Dose Syringe, or the Epinephrine PFS, product, for the emergency treatment of acute anaphylaxis, which is a severe allergic reaction.

According to Adamis Pharmaceuticals Corp on May 28, 2014, it submitted an NDA to the FDA pursuant to Section 505(b)(2) of the Food, Drug & Cosmetic Act, as amended, for approval of the Epinephrine PFS product. The Epinephrine PFS delivers a premeasured dose of ephinephrine for the emergency treatment of anaphylaxis.

Shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) declined to as low as $3.56 per share on March 30, 2015.